Introduction
Insulin-likegrowthfactor-1(IGF-1)hasanti-inflammatoryandpro-repairingpropertiesthatmakeitantiatherogenic [1, 2] .CirculatingIGF-1ismainlyreleasedbytheliv-erundertheregulationofgrowthhormoneandexecutes allofitsphysiologicaleffectsviabindingtoitsreceptor [2] . To date, several studies have already described the importanceofIGF-1onatherosclerosiswithitslargebi-ologicaleffectsandtherapeuticpotential.Althoughthe resultsofthesetrialsareinconclusive,ingeneral,thereis aninverserelationbetweenIGF-1levelsandatheroscle-rosis [2, 3] .Insulin-likegrowthfactor-1reducesoxidative stress, inflammation and atherogenesis in the vasculatureandplaysamajorroleinvasodilatoryresponsesby regulatingnitricoxide(NO)productionintheendotheli-um [2] .No-reflowisanimportantcomplicationofprimary percutaneouscoronaryintervention(PPCI)withpoorclinical outcomes, occurring more frequently in the setting of acute ST-elevation myocardial infarction (STEMI) [4] . The angiographic no-reflow phenomenon is defined as severelyimpairedforwardcoronaryflow(Thrombolysisin MyocardialInfarction(TIMI)<3)intheabsenceofresidualstenosis,dissectionorthrombosis [5] [6] [7] [8] [9] .Althoughthe underlyingmechanismsofno-reflowremainobscure,microvascularplugging,thromboticdebris,cellularedema, reperfusioninjury,endothelialdysfunction,coronaryvasospasmandmicrovascularspasmarelikelytobeclosely related [4, 6, 7, 10] . The prevalence of no-reflow varies from2%upto50%,dependingonthedefinition,recognition methods and selected patient population [6, 11] . Patients with no-reflow tend to experience more early post-infarction complications, heart failure, cardiogenic shock and death [4, 6, 10, 11] . According to our knowledge, there is no study investigating the interactions betweenIGF-1levelsanddevelopmentoftheno-reflow phenomenoninEnglishliterature.
Aim
Thus, we hypothesized that low levels of IGF-1 may be associated with the severity and extent of coronary artery disease (CAD) and development of the coronary no-reflowphenomenoninpatientswithacuteST-elevation myocardial infarction and investigated the role of theIGF-1moleculeinthecoronaryno-reflowphenomenonandseverityofCADinpatientswithacuteSTEMIin atertiaryhospital.
Material and methods

Study patients
This is an observational, case-control comparative study. Patients with STEMI who underwent PPCI within 90 min after first medical contact were included. A total of 113 patients were selected for enrollment in the trial. Forty-nine patients developed no-reflow (group 1). Sixty-four patients did not (group 2). All patients were given similar medical treatment according to related guidelinedirectedmedicaltreatmentapproachesexcept for no-reflow treatment. Exclusion criteria were cardiogenic shock, complete AV block on admission, rescue percutaneous coronary intervention (PCI), intervention onveingrafts,coronarydissection,angiographicallyvisibledistalembolization,severeheartfailure,severebronchospasticdisease,patientswithpreviouspercutaneous revascularization and/or myocardial infarction, severe renalfailure(creatinine>3mg)andliverfailure.Diabetic patientsoninsulintherapyorpoorlycontrolleddiabetic patients(suchasdiabeticketoacidosisandhyperosmolar nonketotic coma), patients with acromegaly or growth hormonedeficiency,patientsonsteroidtherapyandpatientswithknownmalignancywerealsoexcluded.
All patients provided written informed consent and thestudyprotocolwasapprovedbytheethicscommitteeofthehospitalinaccordancewiththeDeclarationof HelsinkiandGoodClinicalPracticeguidelines.
Insulin-like growth factor-1 measurement
Arterial blood (20 ml) was collected from the femoralarterysheathaftercompletingprimarypercutaneous intervention. After the collection, the tubes were centrifuged at 3000 rpm for 10 min and the serum transferredtocappedtubesforstorage.Allaliquotswereanonymizedandstoredfrozenat-40°Cfor6monthsuntil analyzed. All analyses were performed using Siemens Immulite IGF-I assay with solid-phase enzyme labeled chemiluminescentimmunometricassay [12] .Hemolyzed, lipemic and icteric serums were not used for analysis. TheresultoftheIGF1testwasgiveninng/ml.
Coronary angiography
All angiograms were performed with 7 Fr guiding catheterswithoutsideholesataspeedof30framesper second.Coronaryangiographywascarriedoutbyanautomaticmechanicalinjector(ACISTCVi,BraccoImaging S.p.A. Italy). All observations were performed by an interventional cardiologist who was blinded to the study groups.TheTIMIflowscorewasdefinedbythedegree of flow into the epicardial artery as follows: grade 0, completeabsenceofflowbeyondthepointofobstruction;grade1,somecontrastmaterialflowsdistaltothe obstruction but complete arterial visualization is not achieved;grade2,delayedopacificationoftheentireartery;andgrade3,fullpromptvisualizationoftheentire artery [13] .
Coronary artery disease scoring
The severity and extent of CAD were evaluated according to the Gensini score and Syntax score. Gensini scoredependsonthedegreeofthecoronaryarterystenosisanditsgeographicimportance [14] .Thedegreeof luminalnarrowing,concentricityandeccentricityofthe plaquesareevaluated.1pointisgivenfor1-25%steno-sis, 2 points for 26-50%, 4 points for 51-75%, 8 points for 76-90%, 16 points for 91-99%, and 32 points for 100%stenosis.Further,eachlesion'spointismultiplied bythecoefficientwhichisgivenforeachprincipalvascular segment due to the functional significance (the left main coronary artery × 5; the proximal segment of theleftanteriordescendingcoronaryartery(LAD)×2.5; theproximalsegmentofthecircumflexartery×2.5;the mid-segmentoftheLAD×1.5;therightcoronaryartery, thedistalsegmentoftheLAD,theposterolateralartery andtheobtusemarginalartery×1;andothers×0.5),and thesumofallgivesthetotalscore [14] .TheSyntaxscore correspondingtothelesioncomplexitywasmeasuredby thecoronarytreecharacteristicsandthelesionlocations andspecifics [15] .Thescoreismeasuredusingtheopenly accessible web based score calculator (http//www.syntaxscore.com). Scorings were performed and averaged bytwoobserverswhowereblindedtothestudygroups. 
Statistical analysis
StatisticalcalculationswereperformedwithNumber
Discussion
Inthisstudy,theno-refloworslowflowphenomenon wasmostlyseeninpatientswhohavemorediffuseand severe coronary artery disease, with higher Gensini and Syntax scores. The major finding of this study was that IGF-1 levels were not different between the no-reflow group and the control group. Thus, there was no association between the no-reflow phenomenon and IGF-1 levels. There was also no association between Gensini and Syntax scores and IGF-1 levels. Previously published studieshavealreadydemonstratedtheeffectofIGF-1on vascularhomeostasis [2, 3, 16] .Nitricoxideplaysanimportantroleintheregulationofendothelialfunctiondue toitspotentvasodilatoreffectandsensitivityofredoxstatusoftheendothelium [2] .Increasingevidenceindicates thatIGF-1preservesendothelialfunctionandplaysama-jor role in vasodilatory responses by increasing NO production and decreasing oxidative stress and attenuating endothelin-1inducedcontractileresponsesinthevascular endothelium [2] . Endothelial dysfunction, coronary vasospasm and microvascular spasm may play a role in the pathogenesis of the no-reflow phenomenon. Although IGF-1 levels tended to be lower in no-reflow patients in ourstudy,therewasnostatisticallysignificantassociation betweendevelopmentoftheno-reflowphenomenonand IGF-1,whichhaspotentialvasodilatoreffectsonvascular function.Althoughmicrovasculardysfunctionisoneofthe possiblepathophysiologicalmechanismsfortheno-reflow phenomenon [4, 6, 7, 10] , thrombus burden and atheroscleroticdebrisburdenmayplayamoreeffectiverolein developmentoftheno-refloworslowflowphenomenon. Accordingtotheresultsofourstudy,IGF-1maynothave significantcontributiontothedevelopmentofno-reflow or slow flow in patients with STEMI. Insulin-like growth factor-1 also has positive effects on the development of cardiac structures, myocardial contraction, heart beats and ejection fraction and increases cardiac performance and decreases wall tension [17] . Animal studies have shownthatIGF-1hastheabilitytoreducetheatheroscle-roticburdenbyitspleiotropic,antioxidantandantiinflammatoryeffects [1, 2] .LowIGF-1expressionand/orbioavailabilitymayplayaroleinoxidizedLDLinducedcytotoxicity and apoptosis in vascular smooth muscle cells that help plaquedestabilizationandrupture [3] .HighIGF-1,withits receptorandbindingproteins,mayprotecttheatheroscleroticplaqueagainstdestabilizationandrupture [16] .The receptorofIGF-1createsahybridreceptorwiththeinsulin receptor,resultinginmoreIGF-1expression,whichmakes vascularsmoothmusclecellsinsensitivetoinsulin [2] .Low levels of IGF-1 are associated with chronic insulin resistanceandimpairedglucosetolerance [16, 18] .Insulin-like growthfactor-1levelsarealsolowerinpatientswithpoorly controlleddiabetes [1] .Accordingtoseveralstudies,IGF-1 levels are correlated with cardiovascular disease risk in thegeneralpopulation [16] .Ithasbeenreportedthatlow levelsofIGF-1maybeanindependentriskfactorformyo-cardial infarction, coronary artery disease and increased carotid intima-media thickness, and interfere with obesity, insulin resistance, impaired glucose intolerance and leftventricularhypertrophy [18] .However,clinicalstudies have produced conflicting results regarding the relation betweenIGF-IanddifferentformsofCAD [1, [18] [19] [20] .Spallarossa et al. observed decreased IGF-1 levels in patients withadvancedCAD [21] .Burchardtet al.determinedhigher IGF-1levelsinpatientswithadvancedCADthanpatients withhemodynamicallyinsignificantCAD [16] .Theystated thathighIGF-1levelsareaphysiologicalregulatorymech-anismagainstCAD.PatientswithhighIGF-1levelsexperi-encemorestableanginathanacutecoronarysyndromes [22] .Ruotoloet al.demonstratedanindependentassociationbetweenIGF-1levelsandprogressionofCADinyoung malesurvivorsofMI [23] .However,Botkeret al. couldnot show an association between IGF-1 levels and CAD [24] . Similarly,Lawloret al.couldnotshowanyassociationbetweenIGF-1levelsandcoronaryarterydisease [25] .Inour study,therewasnoassociationbetweenIGF-1levelsand theextentandseverityofCAD.Therewasnoassociation betweentheno-reflowphenomenonandIGF-1levels,also, despitethereportsassertingthatIGF-1playsanimportant roleinarterialvasodilatationbycontrollingendothelialNO productionandreducesinflammationandoxidativestress [2, 17] . Changes in lipid profile after acute coronary syndromehavebeenknownforatleast50years [26] .While totalcholesterol,LDLandHDLlevelstendtodecreaseby 0-20%, triglyceride levels increase by 20-30% [26, 27] . Stress-inducedmyocardialdamagealertsadrenergicactivation associated lipolysis and mobilizes free fatty acids [26, 27] .Likewise,LDLlevelswerelowerinpatientswith no-reflowthancontrolsinourstudy.Highercreatininelevelsdetectedintheno-reflowgroupmaybeassociatedwith impairedcoronaryflow.Interestingly,currentsmokershad theno-reflowphenomenonlessofteninourstudy.Accordingtoourstudy,neutrophilcountandNLRmayalsopredict no-reflow, which may be explained by an excessive inflammatoryresponseinno-reflowpatients.TheNLRindexisknowntospecifytheinflammatorystatus [28] .The NLRhasrecentlybeenshownasapredictorofmortalityin patientswithacutemyocardialinfarction,stablepatients with CAD and in patients undergoing PCI and all other conditions [28, 29] . In-hospital mortality was higher in theno-reflowgroup,whohavehigherlevelsofneutrophil countsandNLRinthisstudy.Thenumber,lengthanddiameterofstentsusedwerehigherinno-reflowpatients,also.
Study limitations: Since this was a single-center study limited to PPCI of native vessels, the number of patients was small, representing the major limitation. Anotherlimitationofourstudyisthatunfortunatelywe donothaveenoughsounddataaboutballooninflation pressures and patients' previous medications. Another issue is the high frequency of the no-reflow phenomenoninourstudypopulation,approximately50%ofallpa-tients.Itishighascomparedtodataofotherlargescale studies, even on STEMI patients only [30] . This may be relatedtothemethodologyofevaluationanddefinition ofno-reflow.Sincetheno-reflowgroupincludedpatients withhigherGensiniandSyntaxscores,theslowerflow might be related to some residual stenoses within the infarct-relatedartery.Unfortunately,wewerenotableto usethrombusaspirationcathetersduringthestudyperiod;manualthrombusaspirationmighthavechangedour results.IntheCathPCIRegistry,Harrisonet al.reported thatolderage,STEMI,prolongedintervalfromsymptom onset to intervention, cardiogenic shock, longer lesion length, higher risk class C lesions, bifurcation lesions, andperiproceduralTIMIflowgradewereclinicalandangiographic variables independently associated with developmentoftheno-reflowphenomenon [30] .Sincethe no-reflow phenomenon was blindly evaluated, possible differences do not change the value of results. However, large scale multicenter studies may reveal different results.
Conclusions
In this study, although no-reflow or slow flow was mostly seen in patients with more diffuse and severe CAD,therewasnoassociationbetweendevelopmentof the no-reflow phenomenon and the severity of CAD or IGF-1levels.However,largescalestudiesareneededto verifytheseresults.
